EE537 Cost-Effectiveness of Cemiplimab in Patients With Advanced Basal Cell Carcinoma (aBCC) Who Progressed on or Are Intolerant to a Hedgehog Inhibitor (HHI) in Italy
Abstract
Authors
E Paul PR LaFontaine Y Xu TJ Inocencio K Atsou MC D'Avella J Ader P Guyot C Caisip P Quon CI Chen S Cope